Dr. Shervin Naderi and his team integrate facial rejuvenation with weight loss care to manage the structural facial changes ...

Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, ...

Pennsylvania Governor Josh Shapiro's office has said it is looking to change eligibility for weight loss drugs as part of its ...

Former FDA chief Dr. David Kessler says the new weight-loss drugs are a powerful tool to fight obesity. But they come with ...

Gov. Josh Shapiro’s administration plans to save money by cutting poor patients’ access to expensive weight-loss drugs like ...

Weight-loss medications known as glucagon-like peptide-1 (GLP-1) agonists, which have gained popularity for treating type 2 diabetes and obesity, have been shown to have the surprising secondary ...

Studies have shown the popular weight loss drugs known as GLP-1 agonists may be helpful for more than just curbing appetite — and new research is looking at their potential impact on cancer risk.

Typically, people with obesity who’ve been unable to achieve significant weight loss through nutrition, exercise and medications can also be considered for weight loss surgery. The prerequisites ...

Nick Blackmer is a librarian, fact-checker, and researcher with more than 20 years of experience in consumer-facing health and wellness content. Weight loss medications like Ozempic can have ...

The price of weight loss drugs is falling. Wegovy and Zepbound, which both sell for a list price of more than $1,000 a month, have long been out of reach for people without insurance or whose ...

Some consumers are taking smaller than standard doses of GLP-1s—the popular class of weight-loss and diabetes drugs that include Ozempic, Wegovy, and Zepbound—or spacing out doses longer than ...

As the Food and Drug Administration clamps down on off-brand weight loss medications, Seattle-area residents are stocking up on supplies and fretting about the future of their treatment.